Security
Big Cypress Acquisition Corp. · BCYP
BCYPNASDAQCommon stockHistorical · closed Oct 25, 2021CIK 1833214Updated Oct 14, 2026
Name history
Big Cypress Acquisition Corp. · through Oct 22, 2021
Current security for this SEC filerSABS · NASDAQ
BCYP price & chart
Historical security
This listing closed Oct 25, 2021. Live provider charts are shown only for current listings.
Current security: SABS
About the company
SAB BIO is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. Using advanced genetic engineering and antibody science, SAB BIO developed a proprietary technology which holds the potential to generate additional novel therapeutic candidates utilizing the human immune response, without the need for human donors or convalescent plasma. SAB BIO has optimized genetic engineering in the development of transchromosomic cattle, or Tc-Bovine, to produce hIgG. SAB BIO’s drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, hIgGs that can address a wide range of serious unmet needs in human diseases. The Company’s lead candidate, SAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. SAB-142 is currently being evaluated in newly diagnosed Stage 3 autoimmune T1D patients in a registrational Phase 2b clinical trial called SAFEGUARD. For more informati…
In the news
No coverage from other publishers is available.
Recent filings
Other Events
Items 8.01, 9.01
4 filing
424B3 filing
SCHEDULE 13G/A - filed by PERCEPTIVE ADVISORS LLC regarding SAB Biotherapeutics, Inc.
SCHEDULE 13G/A - filed by Caligan Partners LP regarding SAB Biotherapeutics, Inc.
Show 5 more recent filings
SCHEDULE 13G/A - filed by Commodore Capital LP regarding SAB Biotherapeutics, Inc.
SCHEDULE 13G/A - filed by Vivo Opportunity Fund Holdings, L.P. regarding SAB Biotherapeutics, Inc.
SCHEDULE 13G/A - filed by Woodline Partners LP regarding SAB Biotherapeutics, Inc.
SCHEDULE 13G/A - filed by BALYASNY ASSET MANAGEMENT L.P. regarding SAB Biotherapeutics, Inc.
SCHEDULE 13G - filed by Adage Capital Management, L.P. regarding SAB Biotherapeutics, Inc.
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 172,809,969Source | 44,195,469Source | 83,941,253Source | 68,487,232Source |
| Property, Plant and Equipment, NetUSD | 13,305,902Source | 15,368,009Source | 19,736,519Source | 24,973,432Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 10,502,680Source | 8,897,966Source | 56,566,066Source | 22,408,409Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | — | 0Source | 11,786,420Source |
| Assets, CurrentUSD | 101,052,624Source | 23,792,229Source | 58,906,863Source | 37,184,491Source |
| Prepaid Expense and Other Assets, CurrentUSD | 3,513,384Source | 2,976,562Source | 2,340,797Source | — |
| Operating Lease, Right-of-Use AssetUSD | 2,603,059Source | 970,294Source | 1,277,982Source | 2,351,193Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 21,315,594Source | 18,225,893Source | 26,641,812Source | 27,228,966Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | — | 5Source | 5Source | 0Source |
| Common Stock, Value, IssuedUSD | 4,766Source | 935Source | 929Source | 4,350Source |
| Additional Paid in CapitalUSD | 267,719,445Source | 155,794,142Source | 152,856,874Source | 74,918,250Source |
| Retained Earnings (Accumulated Deficit)USD | -110,895,167Source | -124,168,850Source | -90,063,541Source | -28,143,088Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 186,510Source | -135,410Source | 26,420Source | — |
| Stockholders' Equity Attributable to ParentUSD | 151,494,375Source | 25,969,576Source | 57,299,441Source | 41,258,266Source |
| Liabilities and EquityUSD | 172,809,969Source | 44,195,469Source | 83,941,253Source | 68,487,232Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 10,681,170Source | 7,979,600Source | 10,813,317Source | 19,270,638Source |
| Operating Lease, Liability, CurrentUSD | 797,402Source | 393,430Source | 669,946Source | 1,154,680Source |
| Accounts Payable, CurrentUSD | 3,145,805Source | 1,694,722Source | 945,927Source | 4,981,385Source |
| Operating Lease, Liability, NoncurrentUSD | 1,877,360Source | 581,148Source | 635,777Source | 1,358,829Source |
| Additional Financial Items | ||||
| Deferred Tax Liabilities, NetUSD | 0Source | 0Source | 0Source | — |
| Short-term InvestmentsUSD | 86,089,779Source | 11,862,746Source | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 2,994,763Source | 4,705,771Source | 3,653,151Source | 3,169,429Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 5,210,647Source | 2,941,796Source | 2,423,720Source | 2,674,203Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | -5,556,577Source | -2,454,131Source |
| Increase (Decrease) in Accounts PayableUSD | 1,482,793Source | 923,323Source | -2,701,720Source | -779,425Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -44,775,111Source | -34,292,009Source | -25,119,405Source | -23,459,511Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -121,706,130Source | -11,962,267Source | -152,704Source | -2,090,024Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 933,156Source | 337,262Source | 197,154Source | 2,166,414Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 11,205Source | 24,931Source | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 168,299,452Source | -1,172,626Source | 66,773,137Source | 1,051,411Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 1,604,714Source | -47,668,100Source | 41,519,172Source | -24,498,124Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 242,032Source | 373,954Source | 245,481Source | 293,392Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 5,210,647Source | 2,941,796Source | 2,423,720Source | 2,674,204Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | 15,046,894Source |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | 2,000Source | — | — | — |
| Equity Securities, FV-NI, Gain (Loss)USD | 73,967Source | 26,000Source | — | — |
| Equity Securities, FV-NI, Realized Gain (Loss)USD | 39,694Source | 0Source | — | — |
| Equity Securities, FV-NI, Unrealized Gain (Loss)USD | 32,332Source | — | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | -44,493Source | 15,805Source |
| Gain (Loss) on Termination of LeaseUSD | — | — | — | 32,208Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | 0Source |
| General and Administrative ExpenseUSD | 14,601,031Source | 13,981,263Source | 23,799,306Source | 16,383,285Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 25,629Source |
| InterestExpenseNonoperatingUSD | 240,664Source | 318,401Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | 13,273,683Source | -34,105,309Source | -42,193,786Source | -18,740,804Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 4,261,282Source | -34,105,309Source | -42,193,786Source | — |
| Nonoperating Income (Expense)USD | 62,227,046Source | 8,805,211Source | -4,118,466Source | 10,202,442Source |
| Operating ExpensesUSD | 48,953,363Source | 44,232,930Source | 40,314,311Source | 52,821,798Source |
| Operating Lease, ExpenseUSD | 1,100,000Source | 800,000Source | — | — |
| Other Nonoperating Income (Expense)USD | — | — | — | 33,754Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | 7,680,799Source |
| Proceeds from Stock Options ExercisedUSD | — | 20,409Source | 9,582Source | 76,971Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 0Source | 1,322,410Source | 2,238,991Source | 23,904,181Source |
| Operating Income (Loss)USD | -48,953,363Source | -42,910,520Source | -38,075,320Source | -28,917,617Source |
| Other Nonoperating Income (Expense)USD | — | — | — | 33,754Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 13,273,683Source | — | -42,193,786Source | -18,715,175Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 25,629Source |
| Net Income (Loss) Attributable to ParentUSD | 13,273,683Source | -34,105,309Source | -42,193,786Source | -18,740,804Source |
| Earnings Per Share, BasicUSD per share | 0.22Source | -3.68Source | -7.64Source | -0.43Source |
| Earnings Per Share, DilutedUSD per share | -0.79Source | -3.68Source | -7.64Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 19,311,798Source | 9,261,918Source | 5,521,487Source | 43,524,971Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 61,340,193Source | 9,261,918Source | 5,521,487Source | — |
| Interest Expense (non-operating)USD | 240,664Source | 318,401Source | — | — |
| Additional Financial Items | ||||
| Equity Securities, FV-NI, Realized Gain (Loss)USD | 39,694Source | 0Source | — | — |
| General and Administrative ExpenseUSD | 14,601,031Source | 13,981,263Source | 23,799,306Source | 16,383,285Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | 16,477,797Source | — | — | — |
| Interest ExpenseUSD | — | — | 315,284Source | 301,584Source |
| Interest Income, OtherUSD | 1,432,032Source | 1,285,998Source | 584,966Source | 71,072Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 4,261,282Source | -34,105,309Source | -42,193,786Source | — |
| Nonoperating Income (Expense)USD | 62,227,046Source | 8,805,211Source | -4,118,466Source | 10,202,442Source |
| Operating ExpensesUSD | 48,953,363Source | 44,232,930Source | 40,314,311Source | 52,821,798Source |
| Operating Lease, ExpenseUSD | 1,100,000Source | 800,000Source | — | — |
| Research and Development ExpenseUSD | 34,352,332Source | 30,251,667Source | 16,515,005Source | 36,438,513Source |
| Undistributed Earnings (Loss) Allocated to Participating Securities, BasicUSD | 9,012,401Source | — | — | — |
Filing attachments
sabs-ex99_1.htm · 8-K · 2026-10-13
EXHIBIT 99.1 SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes Fast Track designation recognizes the potential of SAB-142 to address an unmet medical need for people with Stage 3 type 1 diabetes MIAMI, Oct. 13, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that the…
Read attachment ↗p15037704_ex99-1.htm · SCHEDULE 13G · 2026-08-12
EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the …
Read attachment ↗sabs-ex99_1.htm · 8-K · 2026-07-07
EX-99.1 2 sabs-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes MIAMI, July 7, 2026 - Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization and SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for T1D and other autoimmune diseases, today announced that Breakthrough T1…
Read attachment ↗sabs-ex99_1.htm · 8-K · 2026-04-22
EX-99.1 2 sabs-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026 All 4 T1D participants receiving SAB-142 showed C-peptide preservation with 3 of the 4 participants showing a super responder profile concomitant with T cell exhaustion T1D participants receiving SAB-142 showed improved glycemic control MIAMI, April 22, 2026 -- SAB Biotherapeu…
Read attachment ↗sabs-ex4_1.htm · 8-K · 2026-03-19
EX-4.1 3 sabs-ex4_1.htm EX-4.1 EX-4.1 Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK SAB BIOTHERAPEUTICS, INC. Number of Shares: [ ] (subject to adjustment) Warrant No. [ ] Original Issue Date: March [ ], 2026 SAB Biotherapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registere…
Read attachment ↗